Prolonged fasting: safety, refeeding syndrome, and GP screening

Prolonged voluntary fasting — periods of 3–7 days with near-zero energy intake — sits at the edge of what the human body handles safely without medical support. Humans evolved to tolerate brief starvation; the metabolic machinery for ketogenesis, gluconeogenesis, and protein catabolism allows survival for weeks without food under normal conditions. But tolerating starvation is not the same as doing it safely in a modern clinical context, where many patients carry comorbidities, take medications with narrow therapeutic windows, or have nutritional vulnerabilities that make the refeed — not the fast itself — the highest-risk moment. This article outlines what GPs need to know to screen patients who present asking about prolonged fasting and to manage the refeeding phase safely.

A. Core clinical — the AU general-practice framework

Defining prolonged fasting in clinical terms. For the purposes of this article, prolonged fasting means 3–7 days of near-zero voluntary energy intake. This encompasses:

• Water-only fasting: nothing but water and electrolytes for 3–7 days.
• Buchinger-modified fasting: approximately 200–250 kcal/day from vegetable broth and herbal tea, sometimes called “medical fasting” or “therapeutic fasting.” This is the protocol studied in the largest published observational cohort (Wilhelmi de Toledo 2019, PLOS ONE, n=1422).
• Duration cap for outpatient management: 5 days maximum. Six-to-seven-day fasts require residential supervision — not because day 6 is suddenly dangerous, but because electrolyte monitoring, response capability, and medical support cannot be reliably delivered remotely.

The pre-fast GP assessment. The GP consultation before a prolonged fast serves three functions: screening absolute contraindications, ordering baseline investigations, and planning medication management. It is not optional for a 3-day or longer fast.

Absolute contraindications (non-negotiable — do not proceed):

Contraindication	Mechanism / rationale
Type 1 diabetes mellitus	DKA risk without carbohydrate intake; insulin requirements become unpredictable
Any eating disorder history (past or present)	Prolonged fasting is a high-risk behaviour in this cohort; SCOFF screen mandatory first
Pregnancy or breastfeeding	Fetal hypoglycaemia risk; nutritional demands incompatible with prolonged energy restriction
Age <18 or >75 years	Skeletal and neurological development in minors; frailty and fall risk in older adults
BMI <19 kg/m²	Pre-existing nutritional depletion — refeeding syndrome risk at baseline
Known electrolyte disturbance	Fast will compound existing imbalance
CKD stage ≥3b (eGFR <45)	Impaired electrolyte handling; urea/creatinine rise with protein catabolism; contrast-incompatible pathology investigations
Congestive heart failure NYHA III–IV	Intravascular volume shifts during refeed; fluid management complexity
Unstable ischaemic heart disease	QTc prolongation risk with hypokalaemia/hypophosphataemia
Uncontrolled cardiac arrhythmia	Electrolyte changes during fast precipitate events
Active insulin use	Hypoglycaemia; cannot adequately titrate without consistent carbohydrate intake
Sulfonylurea use (gliclazide, glipizide, glimepiride)	Hypoglycaemia; these must be ceased before fasting begins
SGLT2 inhibitor use (canagliflozin, dapagliflozin, empagliflozin)	Euglycaemic DKA risk — this is a documented, potentially fatal, drug-specific risk
Active cancer treatment (chemotherapy/radiotherapy)	Nutritional vulnerability; interaction with treatment-related catabolism
Major surgery within 4 weeks	Tissue healing requires adequate protein and micronutrient availability

Relative contraindications (require case-by-case assessment):

• Controlled type 2 diabetes on metformin only (metformin should be held during fast due to reduced renal clearance at low intake).
• Diuretic use (potassium, sodium, and magnesium monitoring required).
• Anticoagulation (warfarin — INR monitoring needed; DOAC absorption may change).
• Lithium (renal handling altered; levels may rise).
• History of gout (uric acid rises during fasting due to competitive renal tubular excretion with ketone bodies).
• Inflammatory bowel disease (refeed must be guided by gastroenterologist in active or recently active disease).

Baseline investigations before a prolonged fast:

Investigation	Why
Urea + electrolytes + creatinine (U&E/Cr)	Baseline renal function; pre-existing electrolyte disturbance
Magnesium	Often not included in standard U&E; depleted by fasting
Phosphate	Baseline for refeeding syndrome risk stratification
Liver function tests (LFTs)	Fatty liver; hepatic enzyme clearance of ketone bodies
Fasting glucose + HbA1c	Undiagnosed diabetes; glycaemic risk during and after fast
Full blood count (FBC)	Anaemia (iron, B12, folate) — nutritional reserve assessment
ECG (if cardiac risk factors present)	Baseline QTc before electrolyte shifts
SCOFF questionnaire	Eating disorder screen — mandatory before any fast discussion

B. Evidence appraisal — what is actually known about prolonged fasting

The Buchinger observational cohort (Wilhelmi de Toledo 2019, PLOS ONE). The largest safety dataset for prolonged fasting comes from a German-Austrian residential therapeutic fasting programme using the Buchinger Wilhelmi protocol. In this retrospective review of 1,422 patients undergoing 4–21 day fasts:

• Adverse event rate: <1% serious.
• Most common events: hypoglycaemia (mild), fatigue, headache, dizziness.
• No deaths or incidents of severe refeeding syndrome were reported in this supervised cohort.
• Participant selection was rigorous — the absolute contraindications above were applied.

Limitations of the evidence:

• Observational design — no control group, no randomisation, no blinding.
• Setting is highly controlled residential supervision; outcomes may not generalise to unsupervised home fasting.
• Population was predominantly European; metabolic and pharmacological profiles may differ from an Australian general practice population on multiple medications.
• No RCT evidence supports prolonged fasting for any specific medical condition over shorter alternatives (e.g. intermittent fasting, caloric restriction, time-restricted eating).

Mechanism of metabolic adaptation during prolonged fasting (Cahill 2006, Annu Rev Nutr):

• Day 1–2: Glycogen depletion (liver ~100 g, muscle ~400 g); gluconeogenesis begins.
• Day 2–3: Ketogenesis ramps up as fatty acid mobilisation from adipose tissue accelerates; brain begins using ketone bodies as primary fuel.
• Day 3+: Protein catabolism continues (muscle, gut epithelium, immune cells) to supply gluconeogenic precursors; urinary nitrogen rises.
• Day 5–7: Protein catabolism stabilises at ~30–40 g/day in a healthy adult (not zero — the body never fully spares protein during prolonged fasting).

Refeeding syndrome — the highest-risk phase. This is where most serious harms occur, and where the evidence base (NICE CG32, BAPEN 2024 thiamine guidance) is clearest.

During fasting, intracellular phosphate, potassium, and magnesium are progressively depleted as cells catabolise protein and fat for energy. Serum levels may appear normal during the fast because bone and intracellular stores maintain the extracellular concentration. On reintroduction of carbohydrate, insulin surges and drives glucose — accompanied by phosphate, potassium, and magnesium — back into cells, causing precipitous falls in serum concentrations. The critical electrolyte is phosphate: hypophosphataemia below 0.65 mmol/L can cause:

• Cardiac arrhythmia (including fatal ventricular fibrillation).
• Respiratory failure (diaphragmatic weakness).
• Seizures and altered consciousness.
• Rhabdomyolysis.
• Peripheral neuropathy.

C. Refeeding protocol — the NICE CG32 + BAPEN framework applied

Risk stratification. Per NICE CG32, a person completing a 3–7 day prolonged fast meets criteria for high refeeding risk (one or more major risk factors). The protocol below applies:

Days R1–R3 (graduated refeeding):

Day	Energy target	Composition
R1	25–40% of estimated pre-fast daily energy requirement	Carbohydrate-containing small meals every 4–6 h; no large meals
R2	50% of estimated pre-fast daily energy requirement	Increasing variety; include protein at each meal
R3	75% of estimated pre-fast daily energy requirement	Near-normal diet excluding only large volume or high-fat meals
R4+	100% of estimated pre-fast daily energy requirement	Normal diet resumes

Thiamine supplementation (BAPEN 2024 update):

• Thiamine 100 mg orally once daily for 5 days beginning on day R1, before the first carbohydrate-containing meal.
• Rationale: Thiamine is a cofactor for pyruvate dehydrogenase (the enzyme that converts pyruvate to acetyl-CoA). Carbohydrate reintroduction without adequate thiamine causes pyruvate accumulation and Wernicke’s encephalopathy — a preventable neurological emergency. Thiamine is PBS-subsidised (general schedule; no authority required).
• If parenteral nutrition is used or enteral absorption is uncertain: IV thiamine 200–300 mg before the first feed.

Electrolyte monitoring schedule:

Timing	Test	Action threshold
Pre-first-meal (R1 morning)	K, PO4, Mg	If any below threshold: do not feed; treat deficiency; seek hospital review
4–6 h after first substantive meal (R1 afternoon)	K, PO4, Mg	PO4 <0.65: immediate review; K <3.5 or Mg <0.7: oral repletion and monitor
Pre-second-meal (R1 evening or R2 morning)	K, PO4, Mg	Same action thresholds
Daily (R2–R3)	K, PO4, Mg	Can space to every 12 h if stable above threshold

Stop and escalate criteria (contact GP or present to ED):

• Phosphate <0.65 mmol/L at any point.
• Potassium <3.5 mmol/L not responding to oral repletion within 4 hours.
• Magnesium <0.7 mmol/L not responding to oral repletion.
• New peripheral oedema (fluid shifts).
• Hypoglycaemia (blood glucose <4.0 mmol/L) with symptoms.
• Confusion, altered consciousness, or new neurological symptoms.
• Cardiac palpitations, presyncope, or syncope.
• Inability to tolerate oral feeding on day R2 or R3.

D. Australian operations — the GP pathway

Telehealth monitoring during a prolonged fast. For patients who have passed all contraindication screening and proceed with a 3–5 day fast, the GP can offer interim telehealth reviews (MBS item 91790/91891) at day 3 and day 7. These reviews assess:

• Symptom review (headache, dizziness, palpitations, confusion).
• Medication compliance (confirmed cessation of SGLT2i, sulfonylurea, adjusted insulin if relevant).
• Interim electrolyte results if ordered at a community pathology centre.

Relevant MBS items:

• Standard GP consultations: 23 (short), 36 (standard), 44 (long).
• Telehealth GP: 91790 (standard), 91891 (long).
• Chronic disease management plan (if comorbidities): GPCCMP 721/723, Team Care Arrangement 723.
• Dietitian referral under TCA: MBS item 10954 (5 combined allied health visits per calendar year).

Relevant pathology items (MBS, community collection):

• Electrolytes (Na, K, Cl, bicarb): MBS 65070.
• Phosphate: MBS 66500.
• Magnesium: MBS 66512.
• LFTs: MBS 66596.
• Glucose: MBS 66719.
• HbA1c: MBS 66551.
• Full blood count: MBS 65070 (or as part of the panel).
• Urea + creatinine (U&E/Cr): included in standard electrolyte panel or MBS 66683.

PBS items relevant to refeeding:

• Thiamine 100 mg (Vitamin B1): PBS general schedule — no authority required; dispensed at any pharmacy.
• Oral potassium chloride (Span-K, Slow-K): PBS-listed.
• Oral magnesium (various forms): not PBS-listed; available OTC at pharmacies.
• Oral phosphate supplementation: not PBS-listed; Sandoz Phosphate sachets available at compounding pharmacies.

E. Special populations

People with a history of eating disorders. The SCOFF questionnaire (5 questions, score ≥2 = possible eating disorder) must be administered before any fasting discussion in the GP setting. A positive SCOFF screen is an absolute contraindication to prolonged fasting and warrants referral to an eating disorder service. Eating Disorders Victoria and the Butterfly Foundation helpline (1800 33 4673) are AU resources.

People with type 2 diabetes on non-insulin medications. Metformin should be held during a prolonged fast (reduced intake lowers renal clearance, increasing lactic acidosis risk). SGLT2 inhibitors must be ceased at least 3–5 days before a fast (DKA risk persists after cessation due to drug half-life). People on sulfonylureas or GLP-1 receptor agonists require GP medication management before proceeding. People on insulin — of any type — cannot safely undertake prolonged fasting without hospital-level supervision.

Older adults (65–75 years, excluding >75 as absolute contraindication). Muscle loss during a 3–5 day fast is clinically significant in older adults who may already be at sarcopenia threshold. Protein repletion during the refeed (1.2–1.6 g/kg/day from day R2) is a priority. Thiamine deficiency is more common in older adults due to lower dietary intake and increased vulnerability to Wernicke-Korsakoff syndrome; the thiamine protocol is especially important in this group.

People using glucocorticoids. Prolonged fasting in people on chronic corticosteroids carries additional risk of adrenal insufficiency, especially if the steroid dose is tapered as part of a wellness programme — this constitutes adrenal crisis risk. Consult endocrinology or increase corticosteroid dose (“sick day rules”) during any fast exceeding 24–36 hours in steroid-dependent patients.

When to escalate

Escalate immediately (call 000 or present to ED) if any of the following occur at any point during the fast or refeeding period:

• Confusion, altered consciousness, or seizure.
• Chest pain, palpitations, or sustained tachycardia >120 bpm.
• Inability to keep water down (vomiting) — electrolyte depletion becomes unmanageable.
• Phosphate <0.65 mmol/L or potassium <3.0 mmol/L on blood test.
• New peripheral oedema (especially facial or hands — may indicate fluid redistribution).
• Blood glucose <3.5 mmol/L with any symptoms.
• Shortness of breath or weakness out of proportion to expected fatigue.

What this article is and is not

This article provides a clinical framework for the GP management of patients who present seeking information about or having already undertaken prolonged fasting. It is not an endorsement of prolonged fasting as a treatment for any medical condition — the evidence base for specific therapeutic indications compared to less risky alternatives is not established. The refeeding protocol described here is derived from NICE CG32 and the 2024 BAPEN thiamine guidance, which are the current UK clinical standards and are widely used in Australia in the absence of equivalent Australian guidelines. Individual patients require clinical assessment — this article does not replace it. Patients should not undertake a fast of 3 days or more without GP involvement, regardless of how well they feel during the fast.

---

Sources cited

1. Michalsen A, Wilhelmi de Toledo F. Fasting therapy — an expert panel update of the 2002 consensus guidelines. Forsch Komplementmed. 2013;20(6):434–443. doi:10.1159/000357602
2. Wilhelmi de Toledo F, et al. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLOS ONE. 2019;14(1):e0209353. doi:10.1371/journal.pone.0209353
3. NICE Clinical Guideline CG32. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. NICE, 2006 (updated 2017). nice.org.uk/guidance/cg32
4. BAPEN. Thiamine supplementation in refeeding syndrome — updated guidance 2024. British Association for Parenteral and Enteral Nutrition. bapen.org.uk
5. Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ. 2008;336(7659):1495–1498. doi:10.1136/bmj.a301
6. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22. doi:10.1146/annurev.nutr.26.061505.111258
7. Morgan SL, Weinsier RL. Fundamentals of Clinical Nutrition. 2nd ed. Mosby, 1998.
8. Eating Disorders Victoria. SCOFF questionnaire — eating disorder screening tool. 2024. eatingdisorders.org.au
9. HealthDirect. Fasting and your health. Australian Government, 2024. healthdirect.gov.au
10. Better Health Channel. Fasting. Victoria State Government, 2023. betterhealth.vic.gov.au